‘Tirzetta gives our patients direct access to world-class innovations’ - Oksana Drapkina
PROMOMED's Tirzetta® (Tirzepatide) is the first Russian competitor of the well-known and not available in Russia medicine Mounjaro.
The first batches of Tirzetta® (Tirzepatide) from PROMOMED are on sale in Russia. Already now doctors of our country can prescribe the new generation medicine to patients for effective weight loss or treatment of diabetes mellitus. In a few days the medicine will be available on online pharmacy resources first of all and in large pharmacy chains all over the country.
The revolutionary action of Tirzetta® consists in a new quality of weight loss - a pronounced reduction in the volume of fat tissue with careful preservation of muscle corset and formation of physiologically normal, ‘beautiful’, silhouette.
Oksana Drapkina, Academician of the Russian Academy of Sciences, Director of FSBI ‘National Medical Research Center for Therapy and Preventive Medicine’ of the Ministry of Health of Russia, Chief Freelance Specialist in Therapy and General Medical Practice of the Ministry of Health of Russia, Professor, Honoured Doctor of the Russian Federation noted:
‘Obesity is a growing concern for the public health, a it leads to the development of other diseases, such as type 2 diabetes mellitus and cardiovascular diseases, which are among the top ten causes of death in the world. Finding new medicines to treat obesity is essential to improve the health and longevity of the population.
Tirzepatide has demonstrated efficacy in reducing body weight, as well as in reducing the risk of diabetes mellitus, progression of dyslipoproteidaemia, coronary heart disease, arterial hypertension and their complications.
The first domestic tirzepatide (Tirzetta) gives our patients direct access to world-class innovations. This is a breakthrough medicine for the fight against obesity and diabetes. And its potential includes applications in the treatment of rheumatological, cardiological, neurodegenerative and other diseases’.
Tirzepatide, the active substance of Tirzetta® , belongs to the newest class of incretins, which activate two metabolism-regulating receptors - GLP-1 and GIP. Their combined action provides greater selectivity of the mechanism of regulation of metabolism, insulin and glucose levels in the blood and metabolic rate in tissues and organs of the body. As a consequence, body weight is reduced mainly due to accelerated metabolisation of adipose tissue stores.
Tirzetta® is available as a solution for subcutaneous administration (in dosages: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg) in easy-to-use intuitive automatic injectors.
Ilya Bardin-Denisov, General Director of PROMOMED DM LLC, commented: ‘Today we are one step closer to an insulin-free future and healthy longevity for patients with obesity and type II diabetes. ‘The medicine of tomorrow’ - Tirzetta® - has been introduced into civil circulation and is available for use in our country.
The launch of Tirzetta is a consistent and very important step in the implementation of our strategy, announced at the IPO in July 2024, to defeat the most life-threatening diseases - obesity, diabetes, cancer and superinfections.’
The evolution of incretin analogues (physiological regulators of metabolism and appetite) through the sequential development of medicines based on liraglutide, semaglutide and tirzepatide is a global trend and allows - perhaps for the first time in history - to slow down and even reduce the prevalence of obesity and related diseases at the level of entire countries[1].
Tirzetta® has complemented the Company's sought-after endocrinology portfolio (Reduxin®, Reduxin® Forte, Enligria®, Queensenta®, Welgia®), which allows specialists to choose the right medicine for each patient. As scientific data and clinical practice data accumulate, some niches of application are being specified without reducing the overall potential for each medicine.
World practice shows a threefold increase in number of patients treated with incretins. At the same time, the share of tirzepatide in prescriptions for new patients has almost equalled that of semaglutide, and in the USA it has already reached 51%.
According to the analytical company AlphaRM, the market for weight loss medicines in the Russian Federation in 2024 totalled RUB 17 billion, demonstrating a more than 2-fold growth. According to the statistics of the Ministry of Health of the Russian Federation, the number of overweight patients in the country today totals 44 million people, and the change of therapeutic approaches entails a growing need for medicine therapy. PROMOMED implements advanced pharmaco-technological solutions, builds leadership and plans to keep a share of more than 50% in the rapidly growing market of obesity and diabetes mellitus, the volume of which, according to expert estimates, will amount to about 100 billion rubles by 2030. In the tirzepatide market, the Company has emerged with a large lead over competitors, including the respected Lilly, and is targeting 70% of the molecule's market by 2025.
[1] https://jamanetwork.com/journals/jama-health-forum/fullarticle/2827712
